-
Je něco špatně v tomto záznamu ?
Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII
T. Knedlík, B. Vorlová, V. Navrátil, J. Tykvart, F. Sedlák, Š. Vaculín, M. Franěk, P. Šácha, J. Konvalinka,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-12-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-12-01
Open Access Digital Library
od 2011-01-01
Wiley-Blackwell Open Access Titles
od 2011
PubMed
28904865
DOI
10.1002/2211-5463.12276
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate. GCPII expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore, GCPII represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are widely used. However, although mouse GCPII activity has been characterized, a detailed comparison of the enzymatic activity and tissue distribution of the mouse and human GCPII orthologs remains lacking. In this study, we prepared extracellular mouse GCPII and compared it with human GCPII. We found that mouse GCPII possesses lower catalytic efficiency but similar substrate specificity compared with the human protein. Using a panel of GCPII inhibitors, we discovered that inhibition constants are generally similar for mouse and human GCPII. Furthermore, we observed highest expression of GCPII protein in the mouse kidney, brain, and salivary glands. Importantly, we did not detect GCPII in the mouse prostate. Our data suggest that the differences in enzymatic activity and inhibition profile are rather small; therefore, mouse GCPII can approximate human GCPII in drug development and testing. On the other hand, significant differences in GCPII tissue expression must be taken into account when developing novel GCPII-based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism.
Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031952
- 003
- CZ-PrNML
- 005
- 20171103105043.0
- 007
- ta
- 008
- 171025s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/2211-5463.12276 $2 doi
- 035 __
- $a (PubMed)28904865
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Knedlík, Tomáš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. Department of BiochemistryFaculty of ScienceCharles UniversityPragueCzech Republic.
- 245 10
- $a Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII / $c T. Knedlík, B. Vorlová, V. Navrátil, J. Tykvart, F. Sedlák, Š. Vaculín, M. Franěk, P. Šácha, J. Konvalinka,
- 520 9_
- $a Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate. GCPII expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore, GCPII represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are widely used. However, although mouse GCPII activity has been characterized, a detailed comparison of the enzymatic activity and tissue distribution of the mouse and human GCPII orthologs remains lacking. In this study, we prepared extracellular mouse GCPII and compared it with human GCPII. We found that mouse GCPII possesses lower catalytic efficiency but similar substrate specificity compared with the human protein. Using a panel of GCPII inhibitors, we discovered that inhibition constants are generally similar for mouse and human GCPII. Furthermore, we observed highest expression of GCPII protein in the mouse kidney, brain, and salivary glands. Importantly, we did not detect GCPII in the mouse prostate. Our data suggest that the differences in enzymatic activity and inhibition profile are rather small; therefore, mouse GCPII can approximate human GCPII in drug development and testing. On the other hand, significant differences in GCPII tissue expression must be taken into account when developing novel GCPII-based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vorlová, Barbora $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. First Faculty of MedicineCharles UniversityPragueCzech Republic.
- 700 1_
- $a Navrátil, Václav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. Department of BiochemistryFaculty of ScienceCharles UniversityPragueCzech Republic.
- 700 1_
- $a Tykvart, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. Department of BiochemistryFaculty of ScienceCharles UniversityPragueCzech Republic. Present address: Donnelly Centre for Cellular and Biomolecular ResearchUniversity of TorontoTorontoONCanada.
- 700 1_
- $a Sedlák, František $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. First Faculty of MedicineCharles UniversityPragueCzech Republic. Department of Genetics and MicrobiologyFaculty of ScienceCharles UniversityPragueCzech Republic.
- 700 1_
- $a Vaculín, Šimon $u Department of Normal, Pathological and Clinical PhysiologyThird Faculty of MedicineCharles UniversityPragueCzech Republic.
- 700 1_
- $a Franěk, Miloslav $u Department of Normal, Pathological and Clinical PhysiologyThird Faculty of MedicineCharles UniversityPragueCzech Republic.
- 700 1_
- $a Šácha, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic.
- 700 1_
- $a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. Department of BiochemistryFaculty of ScienceCharles UniversityPragueCzech Republic.
- 773 0_
- $w MED00184538 $t FEBS open bio $x 2211-5463 $g Roč. 7, č. 9 (2017), s. 1362-1378
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28904865 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171103105138 $b ABA008
- 999 __
- $a ind $b bmc $g 1255545 $s 992979
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 7 $c 9 $d 1362-1378 $e 20170829 $i 2211-5463 $m FEBS open bio $n FEBS Open Bio $x MED00184538
- LZP __
- $a Pubmed-20171025